On May 20, 2019, Novelion Therapeutics announced that its wholly-owned subsidiary Aegerion Pharmaceuticals, Inc. entered into a plan funding agreement and a restructuring support agreement that will result in Aegerion selling 100% of its reorganized stock to, and becoming a wholly-owned subsidiary of, Dublin-based Amryt Pharma Plc. The agreements, which will result in a recapitalization of Aegerion, are the result of the previously announced capital structure and strategic review by the Boards of Directors of Novelion and Aegerion and a broad marketing process. The recapitalization of Aegerion and a proposed Chapter 11 plan of reorganization has been approved by Aegerion’s board and approved and recommended by the independent restructuring committee of Aegerion’s board. Read full press release here.
Additional information, including copies of the Chapter 11 petitions and other documents filed with the Court are available at: http://cases.primeclerk.com/aegerion